January 8, 2024 02:43 PM EST

Vertex backs out of agreement with CRISPR Therapeutics for stem cell therapy candidate in diabetes

Katherine Lewin

News Reporter

Vertex Pharmaceuticals’ subsidiary ViaCyte is backing out of one of its collaborations with CRISPR Therapeutics on gene-edited stem cell therapies for diabetes.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vertex backs out of agreement with CRISPR Therapeutics for stem cell therapy candidate in diabetes

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Ver­tex backs out of agree­ment with CRISPR Ther­a­peu­tics for stem cell ther­a­py can­di­date in di­a­betes

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Vertex backs out of agreement with CRISPR Therapeutics for stem cell therapy candidate in diabetes